Preparing to launch an asset in an ultra-rare disorder with no other approved therapeutics, a small biotech company requested Promidian’s assistance in researching and developing a global pricing strategy—leveraging local payer insights and learnings from several analog case studies.
The Promidian team initially developed a product-specific market access fact base and defined data gaps to be collected through remaining research.
We then prioritized, researched, and developed five analog pricing case studies informed by secondary research, previous brand experiences, and discussions with industry colleagues.
Next, the Promidian team developed research instruments and stimuli for payers across five global geographies, and we conducted primary research with approximately 35 managed care stakeholders to confirm our pricing assumptions, break-points, and resultant analysis.
Finally, we recommended a pricing strategy, including global list price, to the client.